Novel Sickle Cell Treatment Among 13 New Drugs On Track For EU Approval

A first-of-its-kind drug for uterine fibroids and a new monoclonal antibody treatment for COVID-19 are among several new drugs recommended for pan-EU approval this month.

Thumbs up
Several New Medicines Have Got The Thumbs Up From The EMA • Source: Alamy

The European Medicines Agency has recommended for EU-wide approval 13 new medicines, including two orphans - Global Blood Therapeutics’ first-in-class therapy for sickle cell disease Oxbryta (voxelotor), and Pfizer/Opko Health’s treatment for growth hormone deficiency Ngenla (somatrogon).

The EMA has also recommended for pan-EU approval ObsEva’s Yselty (linzagolix choline), which the company says is a first-of-its-kind drug for uterine fibroids. Also, it adopted a negative opinion...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography